Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China

被引:4
|
作者
Dun, Changchang [1 ,2 ]
Yuan, Meiwen [2 ]
Zhao, Xuelian [2 ]
Hu, Shangying [2 ]
Arbyn, Marc [3 ]
Zhao, Fanghui [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Dept Populat Med, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Epidemiol,Canc Hosp, Beijing, Peoples R China
[3] Sci Inst Publ Hlth, Belgian Canc Ctr, Unit Canc Epidemiol, Brussels, Belgium
来源
CANCER MEDICINE | 2024年 / 13卷 / 11期
关键词
cervical cancer; HPV genotyping; pooled analysis; screening; triage; INTRAEPITHELIAL NEOPLASIA; RISK; WOMEN; PREVALENCE; INFECTION; METAANALYSIS; PERFORMANCE;
D O I
10.1002/cam4.7316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals. Methods: A bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy. Results: A total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks. Conclusions: Our findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Quality of care from a patient perspective in population-based cervical cancer screening
    Tishelman, C
    Lundgren, EL
    Skald, A
    Törnberg, S
    Larsson, BW
    ACTA ONCOLOGICA, 2002, 41 (03) : 253 - 261
  • [42] Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test
    Wright, Thomas C.
    Stoler, Mark H.
    Behrens, Catherine M.
    Sharma, Abha
    Zhang, Guili
    Wright, Teresa L.
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 189 - 197
  • [43] Primary Cervical Cancer Screening With Human Papillomavirus: End of Study Results From the ATHENA Study Using HPV as the First-Line Screening Test
    Wright, Thomas C.
    Stoler, Mark H.
    Behrens, Catherine M.
    Sharma, Abha
    Zhang, Guili
    Wright, Teresa L.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2015, 70 (05) : 321 - 322
  • [44] Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study
    Thomsen, Louise T.
    Kjaer, Susanne K.
    Munk, Christian
    Frederiksen, Kirsten
    Ornskov, Dorthe
    Waldstrom, Marianne
    CLINICAL EPIDEMIOLOGY, 2020, 12 : 203 - 213
  • [45] Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial
    Isidean, Sandra D.
    Mayrand, Marie-Helene
    Ramanakumar, Agnihotram V.
    Gilbert, Laura
    Reid, Stephanie L.
    Rodrigues, Isabel
    Ferenczy, Alex
    Ratnam, Sam
    Coutlee, Francois
    Franco, Eduardo L.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (11) : 2456 - 2466
  • [46] Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
    Castle, Philip E.
    Stoler, Mark H.
    Wright, Thomas C., Jr.
    Sharma, Abha
    Wright, Teresa L.
    Behrens, Catherine M.
    LANCET ONCOLOGY, 2011, 12 (09): : 880 - 890
  • [47] Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study
    Zhao, Yanxia
    Bao, Heling
    Ma, Lan
    Song, Bo
    Di, Jiangli
    Wang, Linhong
    Gao, Yanqiu
    Ren, Wenhui
    Wang, Shi
    Wang, Hai-Jun
    Wu, Jiuling
    BMC MEDICINE, 2021, 19 (01)
  • [48] Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study
    Yanxia Zhao
    Heling Bao
    Lan Ma
    Bo Song
    Jiangli Di
    Linhong Wang
    Yanqiu Gao
    Wenhui Ren
    Shi Wang
    Hai-Jun Wang
    Jiuling Wu
    BMC Medicine, 19
  • [49] Cervical Cancer Screening with DNA-HPV Testing and Precancerous Lesions Detection: A Brazilian Population-based Demonstration Study
    Teixeira, Julio Cesar
    Vale, Diama Bhadra
    Discacciati, Michelle Garcia
    Campos, Cirbia Silva
    Braganca, Joana Froes
    Zeferino, Luiz Carlos
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2023, 45 (01): : 21 - 30
  • [50] Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study
    Gori, S.
    Battagello, J.
    Gustinucci, D.
    Campari, C.
    Zorzi, M.
    Frayle, H.
    Passamonti, B.
    Sartori, G.
    Bulletti, S.
    Fodero, C.
    Cesarini, E.
    Faggiano, R.
    Del Mistro, A.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (08) : 1353 - 1362